Abstract: The present disclosure relates to managing services by a managed service provider (MSP) in a cloud based infrastructure. A control plane of the MSP is established in a first tenancy, and a first access plane of the MSP is established in a second tenancy of a cloud environment. The control plane is configured to manage a plurality of services offered by the MSP to a first host machine included in the second tenancy. A first request is transmitted from the control plane to the first access plane, where the first request is forwarded by the first access plane to the first host machine, and corresponds to a service utilized by the first host machine and managed by the control plane of the MSP. In response to the first request being validated, a first state of the first host machine is modified in the second tenancy based on the first request.

Abstract: The present disclosure relates to managing services by a managed service provider (MSP) in a cloud based infrastructure. A control plane of the MSP is established in a first tenancy, and a first access plane of the MSP is established in a second tenancy of a cloud environment. The control plane is configured to manage a plurality of services offered by the MSP to a first host machine included in the second tenancy. A first request is transmitted from the control plane to the first access plane, where the first request is forwarded by the first access plane to the first host machine, and corresponds to a service utilized by the first host machine and managed by the control plane of the MSP. In response to the first request being validated, a first state of the first host machine is modified in the second tenancy based on the first request.

Abstract: The present disclosure relates to managing services by a managed service provider (MSP) in a cloud based infrastructure. A control plane of the MSP is established in a first tenancy, and a first access plane of the MSP is established in a second tenancy of a cloud environment. The control plane is configured to manage a plurality of services offered by the MSP to a first host machine included in the second tenancy. A first request is transmitted from the control plane to the first access plane, where the first request is forwarded by the first access plane to the first host machine, and corresponds to a service utilized by the first host machine and managed by the control plane of the MSP. In response to the first request being validated, a first state of the first host machine is modified in the second tenancy based on the first request.

Abstract: The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amounts of a pharmaceutically active agent, hydroxypropyl methyl cellulose and a non-ionic, hydrophilic polymer selected froth the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000.

Abstract: This invention relates to methods to prevent worsening of and/or to improve cognitive functioning and behaviour problems in patients with dementia by means of ApoE genotyping to guide the use of AChEI drugs, including rivastigimine. Also included are kits for determining ApoE4 status and recommended treatment strategy.

Abstract: The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amounts of a pharmaceutically active agent, hydroxypropyl methyl cellulose and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000.

Abstract: Private information is removed from dictation so that the transcriptionist never has access to the private information. A software program is used to first extract the private information and then later (after the transcription is completed by, for example, the transcriptionist) reinsert the removed private information back into the final report. This eliminates any possibility of a human in the transcription process accessing the private information.

Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.

Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigmine, in a time-controlled manner.

Abstract: The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amounts of a pharmaceutically active agent, hydroxypropyl methyl cellulose and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000.

Abstract: Bilayer tablet comprising an immediate release first layer comprising an effective amount of oxcarbazepine and at least one pharmaceutically acceptable excipients and a controlled release second layer comprising an effective amount of oxcarbazepine and pharmaceutically acceptable excipients wherein the total amount of oxcarbazepine impurities is less than or equal to about 2% by weight. A process for preparation of controlled release bilayer tablets is capable of delivering oxcarbazepine from one layer immediately followed by a controlled delivery of oxcarbazepine from a matrix forming layer, and a process for preparation of oxcarbazepine bilayer tablets. Bilayer tablets of oxcarbazepine, which maintain a therapeutically effective blood concentration of oxcarbazepine with once a day administration.

Abstract: A novel pharmaceutical dental composition including diclofenac and chlorhexidine gluconate intended for pain associated with various diseases, comprising the diclofenac in its salt form and the chlorhexidine, and in addition a mucoadhesive agent in a pharmaceutically acceptable vehicle providing for bio-adhesion of the composition. One or more local anesthetics such a lidocaine and benzocaine, etc. may also optionally be included.

Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigmine, in a time-controlled manner.

Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.

Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.

Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.

Abstract: The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amounts of a pharmaceutically active agent, hydroxypropyl methyl cellulose and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000.

Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.